SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-014165
Filing Date
2022-05-13
Accepted
2022-05-12 18:15:17
Documents
51
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rgls-20220331.htm   iXBRL 10-Q 1307898
2 EX-31.1 ex-311x20220331.htm EX-31.1 9810
3 EX-31.2 ex-312x20220331.htm EX-31.2 9787
4 EX-32.1 ex-321x20220331.htm EX-32.1 9674
  Complete submission text file 0001628280-22-014165.txt   5441246

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rgls-20220331.xsd EX-101.SCH 37622
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rgls-20220331_cal.xml EX-101.CAL 50249
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rgls-20220331_def.xml EX-101.DEF 215279
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rgls-20220331_lab.xml EX-101.LAB 503746
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rgls-20220331_pre.xml EX-101.PRE 311169
45 EXTRACTED XBRL INSTANCE DOCUMENT rgls-20220331_htm.xml XML 751666
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35670 | Film No.: 22919424
SIC: 2834 Pharmaceutical Preparations